CEBPA and acute myeloid leukemia: As to those with familial AML with CEBPA mutations, favorable outcomes could be achieved by chemotherapy, and those with refractory or relapse disease should receive allo-HSCT to eliminate the germline mutations with related donors without mutations or unrelated donors (Figure 3).